Health Care & Life Sciences » Pharmaceuticals | InDex Pharmaceuticals Holding AB

InDex Pharmaceuticals Holding AB | Balance Sheet

Fiscal year is January-December. All values SEK Thousands.
2014
2015
2016
2017
Cash & Short Term Investments
43,892.00
6,960.00
193,232.00
125,055.00
Total Accounts Receivable
708.00
589.00
643.00
1,092.00
Other Current Assets
828.00
749.00
568.00
693.00
Total Current Assets
45,428.00
8,298.00
194,443.00
126,840.00
Net Property, Plant & Equipment
151.00
56.00
42.00
31.00
Total Investments and Advances
1.00
1.00
1.00
1.00
Total Assets
45,580.00
8,355.00
194,486.00
126,872.00
Accounts Payable
4,411.00
885.00
4,822.00
6,568.00
Other Current Liabilities
10,768.00
6,920.00
12,193.00
15,557.00
Total Current Liabilities
15,179.00
7,805.00
17,015.00
22,125.00
Total Liabilities
15,179.00
7,805.00
17,015.00
22,125.00
Common Equity (Total)
30,401.00
550.00
177,471.00
104,747.00
Total Shareholders' Equity
30,401.00
550.00
177,471.00
104,747.00
Total Equity
30,401.00
550.00
177,471.00
104,747.00
Liabilities & Shareholders' Equity
45,580.00
8,355.00
194,486.00
126,872.00

About InDex Pharmaceuticals Holding AB

View Profile
Address
Tomtebodavägen 23 A
Stockholm AB 171 77
Sweden
Employees -
Website http://www.indexpharma.com
Updated 09/14/2018
InDex Pharmaceuticals Holding AB discovers and develops drugs for the treatment of diseases such as inflammation and cancer. It conducts research, technology development, and commercialization of scientific discoveries in the biomedical field. The firm also develops a platform of patent-protected substances, so-called deoxyribonucleic acid-based ImmunModulatory Sequences, with the potential to be used for the treatment of various immunological diseases.

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.